Welcome to our dedicated page for ALLURION TECHNOLOGIES news (Ticker: ALUR), a resource for investors and traders seeking the latest updates and insights on ALLURION TECHNOLOGIES stock.
Allurion Technologies, Inc. (NYSE: ALUR) is a medical device company focused on metabolically healthy weight loss through its Allurion Program and Allurion Smart Capsule. This news page aggregates company press releases and third-party coverage so readers can review how Allurion communicates progress on its weight-loss platform, clinical studies, regulatory milestones, and capital markets activity over time.
Company announcements frequently highlight developments related to the Allurion Smart Capsule, described as the world’s first and only swallowable, Procedureless™ gastric balloon for weight loss, and the Allurion Virtual Care Suite, which includes the Allurion Mobile App, Allurion Insights with the Iris AI Platform, and the Allurion Connected Scale. News items also cover the company’s strategic focus on metabolically healthy weight loss, including combination approaches with low-dose GLP-1 therapies and efforts to maintain or increase lean body mass in patients with overweight and obesity.
Investors and observers can use this page to follow updates on clinical evidence, such as peer-reviewed publications and case series involving the Smart Capsule, lifestyle interventions, and GLP-1 combination therapy. Allurion’s releases describe multicenter studies, case-controlled analyses, and outcomes related to weight reduction, fat mass loss, visceral fat loss, and body composition.
In addition, Allurion’s news flow includes regulatory and financial milestones, including progress in the FDA PMA process for the Allurion Smart Capsule, FDA inspections, Day-100 meetings, private placements of equity and warrants, and transactions to exchange outstanding debt for convertible preferred equity. Readers interested in ALUR news can consult this feed to see how the company reports on its operating strategy, financial results, and key risk disclosures over time.
Allurion Technologies (NYSE: ALUR) announced a 1-for-25 reverse stock split effective January 3, 2025. The split will reduce outstanding shares from approximately 67.8 million to 2.7 million, with no fractional shares issued. Trading on NYSE will begin on a split-adjusted basis on January 3, 2025.
The decision follows NYSE's notification on August 12, 2024, regarding non-compliance with the minimum $1.00 per share requirement. Proportional adjustments will be made to equity incentive plans, convertible notes, and warrants. Post-split, public warrants (ALUR WS) will be exercisable for 0.056818 shares at $202.50 per share.
Allurion Technologies (NYSE: ALUR) announced that the NYSE has accepted its plan to regain compliance with the exchange's Minimum Market Capitalization Standard. The company, focused on ending obesity, has until March 1, 2026 to meet the listing requirements outlined in Section 802.01B of the NYSE's Listed Company Manual. Dr. Shantanu Gaur, Founder and CEO, expressed satisfaction with this development and emphasized their commitment to increasing shareholder value.
Allurion Technologies (NYSE: ALUR) has launched AllurionMeds, combining compounded GLP-1 medications with an AI-powered platform featuring Coach Iris for weight management. The program includes virtual dietician access and a smart scale measuring weight, muscle, and bone mass. The initiative addresses key GLP-1 challenges: medication adherence, muscle mass loss, and high costs. The program utilizes FDA-registered pharmacies for drug sourcing and expands Allurion's presence to all 50 US states. This launch targets a projected $100 billion GLP-1 market expected to reach 30 million users by 2030.
Allurion Technologies (NYSE: ALUR) reported Q3 2024 financial results with revenue of $5.4 million, down from $18.2 million in Q3 2023. The decline was attributed to destocking, macroeconomic headwinds, and suspended sales in France. The company's AI Virtual Care Suite revenue grew 82% year-over-year. Gross profit margin decreased to 58% from 77% in Q3 2023. The company updated its full-year 2024 revenue guidance to $30-35 million and announced a restructuring plan targeting 50% reduction in operating expenses, aiming for profitability by end of 2025.
Allurion Technologies (NYSE: ALUR) presented significant data at Obesity Week 2024, showcasing results from their largest real-world study involving 19,428 patients across 72 countries. The study demonstrated an average weight reduction of 12.2% after four months using the Allurion Program. Additionally, a second study revealed that patients who previously had unsuccessful results with liraglutide achieved an average 17.6% weight reduction after four months on the Allurion Program. This group included patients where 55% had no weight loss and 45% had less than 5% weight loss with GLP-1 medications.
Allurion Technologies (NYSE: ALUR) has announced it will report its third quarter 2024 financial results on November 13, 2024. The company will host a conference call at 8:30 AM ET on the same day to discuss financial results and provide a business update. Investors can access the call via telephone at (888) 330-3417 (domestic) or +1 646 960 0804 (international) using Conference ID 1905455. A live audio webcast will be available on Allurion's Investor Relations website, with replay options available afterward.
Allurion Technologies (NYSE: ALUR) has submitted the first three modules of its premarket approval application (PMA) to the FDA for the Allurion Balloon, with the fourth and final module containing clinical data from the AUDACITY trial expected early next year. The Allurion Balloon is the world's first swallowable, procedureless gastric balloon for weight loss that requires no surgery, endoscopy, or anesthesia. The device can be placed in 15 minutes during an outpatient visit and naturally passes from the body after four months. Over 150,000 patients have been treated with the balloon outside the US. The AUDACITY trial, involving 550 patients across 17 US sites, completed enrollment ahead of schedule and is expected to conclude by end of 2024.
Allurion Technologies (NYSE: ALUR) has published a study in Clinical Obesity showcasing the effectiveness of the Allurion Program for weight loss and body composition improvement. The study, involving 167 patients with an average BMI of 31.3, demonstrated:
- 15.7% average weight reduction at 4 months
- 17.1% average weight loss at 6 months
- 14.7% average weight loss maintained at 12 months
Notably, patients experienced a significant decrease in body fat percentage from 39% to 35.7% at 6 months, while preserving muscle mass. The study reported no serious adverse events, highlighting the safety and efficacy of the Allurion Balloon in achieving sustainable weight loss and improved body composition.
Allurion Technologies (NYSE: ALUR) has announced the publication of a meta-analysis demonstrating the safety and effectiveness of the Allurion Program for weight loss. The systematic review, which analyzed 11 studies involving 2,107 patients conducted between 2016 and 2024, reported an average weight reduction of 12.5% and a significant BMI reduction of 4.75 kg/m2 at four months.
The analysis also confirmed the safety of the Allurion Balloon, with a low rate of serious adverse events at just 0.90%. Additionally, the study highlighted improvements in metabolic health parameters, including HDL cholesterol, triglycerides, and glycemia. Dr. Ram Chuttani, Chief Medical Officer and Founding Partner of Allurion, emphasized that these results further support the established safety and effectiveness of the Allurion Balloon, which has been documented in 26 peer-reviewed journal articles and used to treat over 150,000 patients worldwide.
Allurion Technologies (NYSE: ALUR), a company focused on ending obesity, has received a continued listing standards notice from the New York Stock Exchange (NYSE). The notice indicates that Allurion is not in compliance with NYSE's listing standards due to its average market capitalization falling below $50 million over a 30-day trading period ending August 29, 2024, and its last reported stockholders' equity being less than $50 million.
Allurion has 45 days to submit a plan to the NYSE outlining actions to regain compliance. If accepted, the company will have an 18-month cure period to meet the standards, during which its stock will continue to trade on the NYSE, subject to compliance with other listing requirements and periodic reviews.